Featured Research

from universities, journals, and other organizations

Regenerated cells may restore vision after corneal dysfunction

Date:
June 14, 2012
Source:
Elsevier Health Sciences
Summary:
Efforts to treat disorders of the corneal endothelium, a single cell layer on the inner surface of the cornea, with regenerative techniques have been less effective. Now, a group of scientists has developed a method that enhances the adhesion of injected corneal endothelial cells, allowing for successful corneal transplantation to repair pathological dysfunctions.

Injection of cultivated corneal endothelial cells with ROCK inhibitor Y-27632 enables regeneration of cornea in rabbit corneal endothelial dysfunction model.
Credit: N. Okumura et al.

Regenerative medicine, or the use of specially grown tissues and cells to treat injuries and diseases, has been successful in treating disorders of a number of organs, including heart, pancreas, and cartilage. However, efforts to treat disorders of the corneal endothelium, a single cell layer on the inner surface of the cornea, with regenerative techniques have been less effective. Now, a group of scientists has developed a method that enhances the adhesion of injected corneal endothelial cells (CECs), allowing for successful corneal transplantation to repair pathological dysfunctions.

Their results are published online June 14 in advance, in the July issue of The American Journal of Pathology.

"Corneal endothelial dysfunction is a major cause of severe visual impairment, since the cells maintain the transparency of the cornea," explains lead investigator Noriko Koizumi, MD, PhD, of the Department of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan. "Injected cultured CECs can be washed off by aqueous humor flow, resulting in poor adhesion of the cells injected onto the corneal tissue. Previous studies demonstrated that Rho-associated kinase (ROCK) signaling interferes with adhesion. We found that transplanting cultivated CECs in combination with a low-molecular weight compound that inhibits ROCK (ROCK inhibitor Y-27632), successfully achieved the recovery of corneal transparency."

Using rabbit cells, researchers cultivated CECs in the lab and injected them into the anterior chamber of rabbit eyes with damaged corneal endothelia. Based on the recovery of the corneal endothelial function, they found that when the cultivated cells were injected along with Y-27632, the rabbit corneas regained complete transparency 48 hours after injection. In contrast, rabbit CECs injected without Y-27632 resulted in hazy and severely swollen corneas. No complications related to cell injection therapy were observed and reconstructed corneal endothelium with Y-27632 exhibited normal hexagonal cell shape.

Since rabbit CECs are highly prolific in vivo, the scientists performed another round of experiments with monkey CECs, which are more similar to those in humans. The transplantation of CECs in these primates also achieved the recovery of long-term corneal transparency with a monolayer of hexagonal cells, suggesting that cell adhesion modified by ROCK inhibitor may be an effective treatment for human corneal endothelial disorders.

Although surgical techniques to replace the injured corneal endothelium have been developed, these procedures are technically difficult and challenging due to a shortage of donor corneas. "The novel strategy of using a cell-based therapy combined with a ROCK inhibitor may ultimately provide clinicians with a new therapeutic modality in regenerative medicine, not only for treatment of corneal endothelial dysfunctions, but also for a variety of pathological diseases," Dr. Koizumi concludes.


Story Source:

The above story is based on materials provided by Elsevier Health Sciences. Note: Materials may be edited for content and length.


Journal Reference:

  1. N. Okumura, N. Koizumi, M. Ueno, Y. Sakamoto, H. Takahashi, H. Tsuchiya, J. Hamuro, and S. Kinoshita. A ROCK Inhibitor Converts Corneal Endothelial Cells into a Phenotype Capable of Regenerating In Vivo Endothelial Tissue. The American Journal of Pathology, 2012 DOI: 10.1016/j.ajpath.2012.03.033

Cite This Page:

Elsevier Health Sciences. "Regenerated cells may restore vision after corneal dysfunction." ScienceDaily. ScienceDaily, 14 June 2012. <www.sciencedaily.com/releases/2012/06/120614082621.htm>.
Elsevier Health Sciences. (2012, June 14). Regenerated cells may restore vision after corneal dysfunction. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/06/120614082621.htm
Elsevier Health Sciences. "Regenerated cells may restore vision after corneal dysfunction." ScienceDaily. www.sciencedaily.com/releases/2012/06/120614082621.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins